| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17512433.2018.1411800 |
| P698 | PubMed publication ID | 29186999 |
| P2093 | author name string | Amrita Das | |
| Ronald G Hall | |||
| Kenna D Payne | |||
| Michelle Ndiulor | |||
| P2860 | cites work | The changing epidemiology of Staphylococcus aureus? | Q22305657 |
| Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus | Q24631182 | ||
| Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection | Q24632307 | ||
| Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh [...] | Q24643277 | ||
| Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines | Q28249905 | ||
| Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People | Q30395441 | ||
| Efficacy and safety of linezolid in liver transplant patients | Q33394330 | ||
| Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients | Q33394332 | ||
| Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. | Q33401050 | ||
| Clinical population pharmacokinetics and toxicodynamics of linezolid | Q33413269 | ||
| Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials | Q33417790 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 | ||
| Livestock-associated methicillin-resistant Staphylococcus aureus in animals and humans | Q34222536 | ||
| Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study | Q34281438 | ||
| Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. | Q34290110 | ||
| Does the dose matter? | Q34347926 | ||
| Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study | Q34428082 | ||
| Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial | Q40155946 | ||
| Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe | Q40443661 | ||
| In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. | Q40447729 | ||
| Epidemiology of Staphylococcus aureus in Italy: First nationwide survey, 2012. | Q40452606 | ||
| Pharmacokinetic/pharmacodynamic research on three different infusion time regimens of linezolid in healthy Chinese volunteers | Q41080765 | ||
| Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model | Q41387743 | ||
| Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection | Q41744271 | ||
| Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial | Q42211543 | ||
| Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria | Q43752948 | ||
| Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers | Q44385718 | ||
| Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme | Q44692777 | ||
| Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens | Q44786393 | ||
| Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis | Q45258208 | ||
| Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients | Q45258847 | ||
| An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications | Q48397434 | ||
| Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy. | Q50895636 | ||
| Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study | Q34486095 | ||
| Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. | Q34529205 | ||
| Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug | Q34548251 | ||
| Tedizolid population pharmacokinetics, exposure response, and target attainment | Q34596353 | ||
| Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment | Q34596658 | ||
| Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid | Q34658779 | ||
| A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. | Q34773796 | ||
| Population pharmacokinetics of linezolid in patients treated in a compassionate-use program | Q34824166 | ||
| Linezolid pharmacokinetics in adult patients with cystic fibrosis | Q35006010 | ||
| Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis | Q35065732 | ||
| In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model | Q35065908 | ||
| Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model | Q35364245 | ||
| Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections | Q35542330 | ||
| Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens | Q35565851 | ||
| Pharmacokinetics of doxycycline in adults with cystic fibrosis | Q35666485 | ||
| Pharmacokinetics of linezolid in subjects with renal dysfunction | Q35685516 | ||
| In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia. | Q36075813 | ||
| Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus | Q36094861 | ||
| Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature | Q36103613 | ||
| Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. | Q36243256 | ||
| Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis | Q36468134 | ||
| Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults | Q36667074 | ||
| Pharmacokinetics and pharmacodynamics of antibacterial agents | Q36911111 | ||
| Methicillin-Resistant Staphylococcus aureus Recovered from Healthcare- and Community-Associated Infections in Egypt. | Q37084387 | ||
| Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults | Q37120010 | ||
| Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis | Q37461431 | ||
| Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature | Q38106836 | ||
| Tedizolid for the management of human infections: in vitro characteristics. | Q38171762 | ||
| Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus | Q38445030 | ||
| Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial | Q38456150 | ||
| In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center | Q38741373 | ||
| Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review | Q39013332 | ||
| Clinical pharmacokinetics of doxycycline and minocycline | Q39571569 | ||
| Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers | Q39910014 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1-11 | |
| P577 | publication date | 2017-11-30 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options). |
Search more.